- Home
- BROG vs FATE Comparison
BROG vs FATE Comparison
Compare BROG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- FATE
- Stock Information
- Founded
- BROG 2019
- FATE 2007
- Country
- BROG United Arab Emirates
- FATE United States
- Employees
- BROG N/A
- FATE N/A
- Industry
- BROG Integrated oil Companies
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BROG Energy
- FATE Health Care
- Exchange
- BROG Nasdaq
- FATE Nasdaq
- Market Cap
- BROG 131.5M
- FATE 152.4M
- IPO Year
- BROG N/A
- FATE 2013
- Fundamental
- Price
- BROG $1.28
- FATE $1.03
- Analyst Decision
- BROG
- FATE Hold
- Analyst Count
- BROG 0
- FATE 8
- Target Price
- BROG N/A
- FATE $5.43
- AVG Volume (30 Days)
- BROG 6.0K
- FATE 2.1M
- Earning Date
- BROG 05-20-2025
- FATE 05-12-2025
- Dividend Yield
- BROG N/A
- FATE N/A
- EPS Growth
- BROG N/A
- FATE N/A
- EPS
- BROG N/A
- FATE N/A
- Revenue
- BROG $73,020,415.00
- FATE $13,631,000.00
- Revenue This Year
- BROG N/A
- FATE N/A
- Revenue Next Year
- BROG N/A
- FATE N/A
- P/E Ratio
- BROG N/A
- FATE N/A
- Revenue Growth
- BROG N/A
- FATE N/A
- 52 Week Low
- BROG $0.80
- FATE $0.66
- 52 Week High
- BROG $2.14
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- BROG 55.48
- FATE 46.14
- Support Level
- BROG $1.15
- FATE $0.91
- Resistance Level
- BROG $1.28
- FATE $1.34
- Average True Range (ATR)
- BROG 0.06
- FATE 0.15
- MACD
- BROG 0.01
- FATE -0.03
- Stochastic Oscillator
- BROG 81.25
- FATE 20.69
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.